2020 Newsletter
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Mechanisms of Planar Cell Polarity, Growth and the Hippo Pathway
Developmental Biology 377 (2013) 1–8 Contents lists available at SciVerse ScienceDirect Developmental Biology journal homepage: www.elsevier.com/locate/developmentalbiology Review The mechanisms of planar cell polarity, growth and the Hippo pathway: Some known unknowns Peter A. Lawrence n, Jose´ Casal Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3 EJ, United Kingdom article info abstract Article history: Planar cell polarity (PCP) is a small but important area of research. In this review we discuss a limited Received 18 December 2012 number of topics within the PCP field, chosen because they are difficult, unsolved, controversial or just Received in revised form because we find them interesting. Because Drosophila is the best studied and technically most amenable 26 January 2013 system we have concentrated on it, but also consider some examples from work on vertebrates. Topics Accepted 28 January 2013 discussed include the number of genetic pathways involved in PCP, as well as the causal relationship between embryonic axes, gradients of morphogens and PCP itself. We consider the vexed question of Keywords: the roles of the Wnt genes in PCP in both vertebrates and Drosophila. We discuss whether the proteins Planar cell polarity involved in PCP need to be localised asymmetrically in cells in order to function. We criticise the way Growth the Hippo pathway is described in the literature and ask what its wildtype function is. We explore Gradients afresh how the Hippo pathway might be linked both to growth and to PCP through the gigantic Morphogens Hippo cadherin molecule Fat. We offer some new ways of making sense of published results, particularly Fat those relating to the Frizzled/Starry night and Dachsous/Fat systems of PCP. -
Lecture Slides
(J. American Chemical Association, 78, 3458-3459) The Secondary Structure of Complementary RNA E. Peter Geiduschek, John W. Moohr, and Smauel B. Weiss, Proceedings of The National Academy of Sciences, 48, 1078-1086, 1962. R.H. DOI RH, and S. SPIEGELMAN Homology test between the nucleic acid of an RNA virus and the DNA in the host cell. Science 1962 Dec 14 1270-2. MONTAGNIER L, SANDERS FK. REPLICATIVE FORM OF ENCEPHALOMYOCARDITIS VIRUS RIBONUCLEIC ACID. Nature. 1963 Aug 17;199:664-7. (Science 143, 1034-1036, March 6, 1964) WARNER RC, SAMUELS HH, ABBOTT MT, KRAKOW JS. (1963) Ribonucleic acid polymerase of Azotobacter vinelandii, II. Formation of DNA- RNA hybrids with single-stranded DNA as primer. Proc Natl Acad Sci U S A. 49:533-8. Double Stranded RNA as a Specific Biological Effector December 8, 2006 Karolinska Institute, Stockholm, Sweden Viral interference (Interferon) effects in animals M. Hoskins (1935) A protective action of neurotropic against viscerotropic yellow fever virus in Macacus rhesus. American Journal of Tropical Medicine, 15, 675-680 G. Findlay and F. MacCallum (1937) An interference phenomenon in relation to yellow fever and other viruses. J. Path. Bact. 44, 405-424. A. Isaacs and J. Lindenmann (1957) Virus Interference. I. The Interferon Proc. Royal Soc. B 147, 268-273. Proceedings of the National Academy of Sciences, USA, Volume 58, Pages 782-789. 1967 Promoter Make transgenic worms geneX Antisense Transcripts Interference (Development 113:503 [1991]) geneX Promoter Make transgeneic worms geneX SENSE Transcripts Also Interference! (Development 113:503 [1991]) In Vitro Promoter Make RNA in vitro geneX Antisense RNA Inject worm gonad Interference! (Guo and Kemphues, 1995) In Vitro geneX Promoter Make RNA in vitro geneX SENSE RNA Inject worm gonad Also Interference! (Guo and Kemphues, 1995) Craig Mello's RNAi Workshop: 1997 C. -
An Assessment of Progress in Human Genome Programmes Worldwide (A Support Study for the Evaluation of the EC Human Genome Analysis Programme)
EUR 15. U \Z$ ISSN 1018-5593 European Commission An assessment of progress in Human Genome Programmes worldwide (A support study for the evaluation of the EC Human Genome Analysis Programme) Report Research evaluation EUR 15412 EN European Commission An assessment of progress in Human Genome Programmes worldwide (A support study for the evaluation of the EC Human Genome Analysis Programme) Authors: B.R. Jordan The opinions contained in this report are the sole responsibility of the author and do not necessarily reflect the official position of the European Commission. " """'"■■""■•»»Τ*«»*«»··!·»—■-■w·^·^ 1994 NC EUR 15412 EN C1. Published by the EUROPEAN COMMISSION DIRECTORATE GENERAL XIII Telecommunications, Information Market and Exploitation of Research L-2920 Luxembourg LEGAL NOTICE Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of the following information Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1994 ISBN 92-826-8226-9 © ECSC-EC-EAEC Brussels · Luxembourg, 1994 Printed in Belgium TABLE OF CONTENTS FOREWORD I. INTRODUCTION 1 Π. REVIEW OF MAJOR NATIONAL PROGRAMMES 5 Π A. UNITED STATES 5 Π A 1. Current plan and major participants Π A 2. Assessment of progress A caveat The DOE juggernaut The NIH kaleidoscope Π A 3. General comments (scientific) Genetic maps Physical maps Cytogenetics Sequencing Π A 4. General comments (organizational) DOE vs NIH Manpower Informatics and instrumentation Π A 5. Recent developments Π Β. JAPAN 11 Π Β 1. Current plan and major participants Π Β 2. -
Human Genome Project
MARCH 2002 Managing “Big Science”: A Case Study of the Human Genome Project W. Henry Lambright Professor of Political Science and Public Administration and Director, Center for Environmental Policy and Administration The Maxwell School Syracuse University The PricewaterhouseCoopers Endowment for New Ways to Manage Series Ways New The Business of Government NEW WAYS TO MANAGE SERIES Managing “Big Science”: A Case Study of the Human Genome Project W. Henry Lambright Professor of Political Science and Public Administration and Director, Center for Environmental Policy and Administration The Maxwell School Syracuse University March 2002 1 TABLE OF CONTENTS Foreword..............................................................................................3 Executive Summary ..............................................................................4 The Human Genome Project Today......................................................6 The Human Genome Project: A Management Case History ..............10 Conceptualization, 1980–86 ..........................................................11 Adoption, 1986–90 ........................................................................13 Initial Implementation, 1990–93 ....................................................15 Maintaining Momentum and Growing, 1993–98 ..........................17 Reorientation, 1998–2001..............................................................20 Conclusions........................................................................................27 Goals ............................................................................................27 -
Sign-On Letter to Ask World Health Organization Executive Board Members to Support the Resolution on A
Sign-on Letter to ask World Health Organization Executive Board members to support the resolution on a "Global Framework on Essential Health Research and Development" proposed by the Republic of Kenya at the January 2006 meeting. January 25th, 2006 Open Letter to the WHO Executive Board Dear Members of the WHO Executive Board: As scientists, many of whom work in fields connected with biomedicine, we are writing to express our support for the resolution submitted by the Republic of Kenya at the 117th meeting of the WHO Executive Board on January 23rd 2006. Although we have very varied scientific backgrounds, from basic research to specific clinical research, we are all deeply concerned with deficiencies in the way that biomedical research science is supported and translated into treatments that improve health outcomes around the world. In the research setting we see many possibilities to develop drugs to treat neglected diseases, but a lack of sustainable support for the R&D process. In the clinical setting we see the problem of affordable drugs to a greater or lesser extent in health care systems in all countries. At a time of huge progress in basic research science and more money being spent on biomedical R&D than ever, we are deeply concerned about the ability of existing mechanisms to translate this into a global improvement in public health. We have all felt the impact and promise of the free availability of genome sequence data, notably from the human genome project. At the same time we see research activities increasingly complicated by legal restrictions, such as intellectual property rights, which can interfere with free data exchange and can limit biomedical research progress. -
The Scientific Century: Securing Our Future Prosperity
The Royal Society For further information prosperity future our securing Century: Scientific The The Royal Society is a Fellowship of more than 1400 outstanding The Royal Society individuals from all areas of science, mathematics, engineering and Science Policy Centre medicine, who form a global scientific network of the highest calibre. The 6–9 Carlton House Terrace Fellowship is supported by over 130 permanent staff with responsibility for London SW1Y 5AG the day-to-day management of the Society and its activities. The Society T +44 (0)20 7451 2500 encourages public debate on key issues involving science, engineering F +44 (0)20 7451 2692 and medicine, and the use of high quality scientific advice in policymaking. E [email protected] We are committed to delivering the best independent expert W royalsociety.org advice, drawing upon the experience of the Society’s Fellows and Foreign Members, the wider scientific community and relevant stakeholders. In our 350th anniversary year and beyond we are working to achieve five strategic priorities: • Invest in future scientific leaders and in innovation • Influence policymaking with the best scientific advice • Invigorate science and mathematics education The Royal Society Royal The • Increase access to the best science internationally • Inspire an interest in the joy, wonder and excitement of scientific discovery March 2010 March The Scientific Century ISBN 978-0-85403-818-3 02/10 report Centre Policy Science securing our future prosperity ISBN: 978-0-85403-818-3 Issued: March -
Half-Century in the Life Sciences A
EMBO in perspective A half-century in the life sciences EMBO in perspective A half-century in the life sciences EMBO is an organization of more than 1600 leading researchers that promotes EMBO is an organization of more than 1600 leading researchers excellence in the life sciences. Since it that promotes excellence in the life sciences. Over the past 50 years, was founded in 1964, it has made many it has grown significantly from the early pioneering days of molecular contributions to promote the development biology and made many contributions to promote the development of research in Europe and beyond. of the life sciences. When EMBO officially acquired legal Based on personal interviews with Sydney Brenner, L. Luca Cavalli- status on 12 July 1964, its first goal was Sforza, Georges Cohen, James Watson and the directors of EMBO, Georgina Ferry to establish networking activities to this book tells the story of the journey from the study of molecules encourage interactions between European Georgina Ferry is a science writer based and microbes in the nuclear age to the growth and expansion of laboratories. The provision of fellowships in Oxford. Her work includes articles for EMBO and the life sciences. It also provides new perspectives on and the election of the first members proved New Scientist, Nature and The Guardian, some of the creation myths of the organization. science broadcasts for BBC Radio, and extremely beneficial for life scientists in web content projects for the Wellcome Europe. A second objective was to create a EMBO IN PERSPECTIVE EMBO Library and the Science Museum, central laboratory for molecular biology, a London. -
Transformative Technology in Engineering and Medicine
JOHNS HOPKINS DEPARTMENT OF MEDICINE & WHITING SCHOOL OF ENGINEERING RESEARCH RETREAT 2021 TRANSFORMATIVE TECHNOLOGY IN ENGINEERING AND MEDICINE Thursday, March 11 at 9:30 a.m. Friday, March 12 at 8:15 a.m. Department of Medicine Whiting School of Engineering Welcome to the Johns Hopkins 2021 Department Of Medicine/ Whiting School of Engineering Research Retreat he Department of Medicine/Whiting School of Engineering Research Retreat is about connections. Connections among researchers in both schools, connections between Tmentors and mentees, and connections between leadership and the adventurous researchers that elevate the discovery community. Our annual retreat is the largest forum for the presentation of research by Department of Medicine and Whiting School of Engineering faculty and trainees and one of the largest research events throughout Johns Hopkins. The retreat has a long-standing history in the Department of Medicine, but has seen its greatest success since joining forces with the Whiting School of Engineering in 2018. This year, we will explore “Transformative Technology in Engineering and Medicine.” The keynote address will be given by Dr. Jennifer Doudna, who won the 2020 Nobel Prize for Chemistry. Other featured speakers include Taekjip Ha, PhD, Bloomberg Distinguished Professor from the Department of Biophysics and Biophysical Chemistry and Alison Moliterno, MD, Associate Professor of Medicine. We will also continue our Spotlight on Research sessions featuring short presentations from select faculty from medicine and engineering. We know this year’s retreat looks a little different in its virtual format, but we are confident the exposure to the bold and creative research directions at Johns Hopkins will fuel new collaborations and capitalize on the investigative strengths of each enterprise. -
Genome Editing and Human Reproduction
Genome editing and human reproduction Previous Nuffield Council publications Non-invasive prenatal testing: ethical issues Genetic screening: a supplement to the 1993 report Published March 2017 by the Nuffield Council on Bioethics Published July 2006 Genome editing: an ethical review Published September 2016 The ethics of research involving animals Published May 2005 Children and clinical research: ethical issues Published May 2015 The ethics of research relating to healthcare in developing countries: a follow-up Discussion Paper The collection, linking and use of data in biomedical Published March 2005 research and health care: ethical issues Published February 2015 The use of genetically modified crops in developing countries: a follow-up discussion paper The findings of a series of engagement activities Published December 2003 exploring the culture of scientific research in the UK Published December 2014 Pharmacogenetics: ethical issues Published September 2003 Novel neurotechnologies: intervening in the brain Published June 2013 Genetics and human behaviour: the ethical context Published October 2002 Donor conception: ethical aspects of information sharing The ethics of patenting DNA: a discussion paper Published April 2013 Published July 2002 Emerging biotechnologies: technology, choice and The ethics of research related to healthcare in the public good developing countries Published December 2012 Published April 2002 Novel techniques for the prevention of mitochondrial Stem cell therapy: the ethical issues – a discussion DNA disorders: